convalescent plasma-Stony Brook University-COVID-19

Convalescent plasma-Stony Brook University-COVID-19 is an investigational biologic therapy developed by Stony Brook University for the treatment of hospitalized patients with COVID-19. This passive immunotherapy involves the transfusion of high-titer antibody-rich plasma collected from individuals who have recovered from SARS-CoV-2 infection. The plasma contains immunoglobulins, primarily IgG, that target viral antigens such as the nucleocapsid protein and the spike protein, aiming to neutralize the virus and reduce disease severity. The therapy was evaluated in a Phase 1/2 randomized controlled trial led by Stony Brook Medicine to assess its safety and efficacy compared to standard donor plasma, utilizing specific antibody titer thresholds for donor selection.

Other names

anti-SARS-CoV-2 convalescent plasmaanti-SARS-CoV2 convalescent plasmaanti-SARS-CoV 2 convalescent plasmahigh-titer anti-SARS-CoV-2 plasmaStony Brook Convalescent Plasma